Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody
Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L. Levy Place, Box 1079, New York, NY, 10029-6574, USA, Email darren.pan@mountsinai.orgAbstract: Te...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-07-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/teclistamab-for-multiple-myeloma-clinical-insights-and-practical-consi-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1827894663938310144 |
|---|---|
| author | Pan D Richter J |
| author_facet | Pan D Richter J |
| author_sort | Pan D |
| collection | DOAJ |
| description | Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L. Levy Place, Box 1079, New York, NY, 10029-6574, USA, Email darren.pan@mountsinai.orgAbstract: Teclistamab is a BCMAxCD3 bispecific antibody, the first approved for the treatment of relapsed or refractory multiple myeloma. Given its impressive efficacy in heavily pretreated patients and better accessibility compared to BCMA-directed CAR T cells, teclistamab is sure to become a staple of relapsed/refractory multiple myeloma therapy. Teclistamab carries a set of notable adverse effects including cytokine release syndrome (CRS), infections, and neurotoxicity for which providers must take unique precautions and prophylactic measures. Here, we review the preclinical and clinical data, which led to teclistamab’s approval, important patient selection considerations, strategies for managing CRS and other side effects, and finally the future of bispecific antibody therapy in multiple myeloma.Keywords: teclistamab, bispecific antibody, multiple myeloma, BCMA |
| first_indexed | 2024-03-12T22:09:50Z |
| format | Article |
| id | doaj.art-426677e3b8bd494ebe1400a1b5d88d2c |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-03-12T22:09:50Z |
| publishDate | 2023-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-426677e3b8bd494ebe1400a1b5d88d2c2023-07-23T15:49:04ZengDove Medical PressCancer Management and Research1179-13222023-07-01Volume 1574175185314Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific AntibodyPan DRichter JDarren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L. Levy Place, Box 1079, New York, NY, 10029-6574, USA, Email darren.pan@mountsinai.orgAbstract: Teclistamab is a BCMAxCD3 bispecific antibody, the first approved for the treatment of relapsed or refractory multiple myeloma. Given its impressive efficacy in heavily pretreated patients and better accessibility compared to BCMA-directed CAR T cells, teclistamab is sure to become a staple of relapsed/refractory multiple myeloma therapy. Teclistamab carries a set of notable adverse effects including cytokine release syndrome (CRS), infections, and neurotoxicity for which providers must take unique precautions and prophylactic measures. Here, we review the preclinical and clinical data, which led to teclistamab’s approval, important patient selection considerations, strategies for managing CRS and other side effects, and finally the future of bispecific antibody therapy in multiple myeloma.Keywords: teclistamab, bispecific antibody, multiple myeloma, BCMAhttps://www.dovepress.com/teclistamab-for-multiple-myeloma-clinical-insights-and-practical-consi-peer-reviewed-fulltext-article-CMARteclistamabbispecific antibodymultiple myelomabcma |
| spellingShingle | Pan D Richter J Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody Cancer Management and Research teclistamab bispecific antibody multiple myeloma bcma |
| title | Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody |
| title_full | Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody |
| title_fullStr | Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody |
| title_full_unstemmed | Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody |
| title_short | Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody |
| title_sort | teclistamab for multiple myeloma clinical insights and practical considerations for a first in class bispecific antibody |
| topic | teclistamab bispecific antibody multiple myeloma bcma |
| url | https://www.dovepress.com/teclistamab-for-multiple-myeloma-clinical-insights-and-practical-consi-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT pand teclistamabformultiplemyelomaclinicalinsightsandpracticalconsiderationsforafirstinclassbispecificantibody AT richterj teclistamabformultiplemyelomaclinicalinsightsandpracticalconsiderationsforafirstinclassbispecificantibody |